Cell Therapy

R&D

Purity, potency, and safety – affordably – in stem cell ther...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s

Oncology

Move over CAR-T: The potential of NK cells in cell therapy

The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren't the only option for cell th

News

FDA clears BMS’ Breyanzi for follicular lymphoma

Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (

R&D

Lung-I Cheng interview with Jonah Comstock at Reuters

Reuters Pharma USA 2024 – Lung-I Cheng

Cell and gene therapies were a major topic of discussion this year at Reuters Pharma USA in Philadelphia.

News

New era for cell therapy as FDA OKs first for solid tumours

Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.

R&D